{
    "clinical_study": {
        "@rank": "16621", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Prednisone 10 mg tablet on Day 1 and 7; VX-509 200 mg tablets on Days 2 thru 7"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Methylprednisolone 8 mg tablet on Day 1 and 7; VX-509 200 mg tablets on Days 2 thru 7"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the effect of VX-509 on the pharmacokinetics (PK) of\n      corticosteroids (prednisone or methylprednisolone) and the effect of corticosteroids on the\n      PK of VX-509 and its metabolite. The study will also evaluate the safety and tolerability of\n      VX-509 when coadministered with each of these corticosteroids."
        }, 
        "brief_title": "Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Drug Interactions", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male subjects between 18 and 55 years of age, inclusive\n\n          -  Body mass index (BMI) of 18.0 to 31.0 kg/m2, inclusive, and a total body weight >50\n             kg\n\n        Exclusion Criteria:\n\n          -  History of any illness that, in the opinion of the investigator or the subject's\n             general practitioner, might confound the results of the study or pose an additional\n             risk in administering study drug(s) to the subject. This may include, but is not\n             limited to, history of cardiovascular or central nervous system disease, diabetes,\n             history or presence of clinically significant pathology, or history of mental disease\n\n          -  Treatment with an investigational drug within 30 days or 5 half-lives preceding the\n             first dose of study drug\n\n          -  Subject has a female partner who is pregnant, nursing, or planning to become pregnant\n             during the study or within 90 days of the last dose of study drug\n\n          -  Positive test result for any of the following infectious disease tests at the\n             Screening Visit: T-SPOT tuberculosis (TB) test, hepatitis B surface antigen,\n             hepatitis C virus antibody, and human immunodeficiency virus 1 and 2 antibodies"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01886209", 
            "org_study_id": "VX13-509-010"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort 1", 
                "intervention_name": "Prednisone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2"
                ], 
                "intervention_name": "VX-509", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "intervention_name": "Methylprednisolone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone", 
                "Prednisone", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lenexa", 
                    "country": "United States", 
                    "state": "Kansas"
                }, 
                "name": "Vertex Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label, Phase 1 Study to Examine the Pharmacokinetic Interactions Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Vertex Pharmaceuticals Incorporated", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "PK parameters including Cmax, area under the concentration-time curve from the time of dosing extrapolated to infinity (AUC0 \u221e), and AUC0-last for prednisone and its metabolite prednisolone with or without VX-509", 
                "safety_issue": "No", 
                "time_frame": "Multiple blood samples will be obtained over the 10 day open-label treatment phase"
            }, 
            {
                "measure": "PK parameters including Cmax, area under the concentration-time curve from the time of dosing extrapolated to infinity (AUC0 \u221e), and AUC0-last for methylprednisolone with or without VX-509", 
                "safety_issue": "No", 
                "time_frame": "Multiple blood samples will be obtained over the 10 day open-label treatment phase"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01886209"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Treatment-emergent adverse events, results of clinical laboratory tests, vital signs, and 12-lead electrocardiograms", 
            "safety_issue": "No", 
            "time_frame": "Up to 18 days"
        }, 
        "source": "Vertex Pharmaceuticals Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vertex Pharmaceuticals Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}